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Abstract	
	
The	concept	of	a	reference	case,	first	proposed	by	the	US	Panel	on	Cost-
Effectiveness	in	Health	and	Medicine,	has	been	used	to	specify	the	required	
methodological	features	of	economic	evaluations	of	health	care	interventions.	In	the	
case	of	gene	therapy,	there	is	a	difference	of	opinion	on	whether	a	specific	
methodologic	reference	case	is	required.	The	aim	of	this	paper	is	to	provide	a	more	
detailed	analysis	of	the	characteristics	of	gene	therapy	and	the	extent	to	which	these	
characteristics	warrant	modifications	to	the	methods	suggested	in	general	reference	
cases	for	economic	evaluation.	We	argue	that	a	completely	new	reference	case	is	
not	required,	but	propose	a	tailored	checklist	that	can	be	used	by	analysts	and	
decision-makers	to	determine	which	aspects	of	economic	evaluation	should	be	
considered	further,	given	the	unique	nature	of	gene	therapy.	
	
	 	
1.	Introduction	and	Motivation	
	
The	concept	of	a	‘reference	case’,	first	proposed	by	the	US	Panel	on	Cost-
Effectiveness	in	Health	and	Medicine	(1),	has	been	used	to	specify	the	required	
methodological	features	of	economic	evaluations	of	health	care	interventions	in	
different	jurisdictions	(2,3).	In	the	US,	the	Institute	for	Clinical	and	Economic	Review	
(ICER)	has	recently	produced	a	reference	case	that	is	based,	in	part,	on	the	Second	
US	Panel	(4).	The	rationale	for	the	reference	case	is	to	improve	the	quality	and	
comparability	of	cost-effectiveness	analyses	through	the	incorporation	of	standard	
methodological	practices.		However,	as	others	have	noted,	the	same	economic	
evaluation	methods	may	not	be	equally	applicable	to	every	type	of	medical	
intervention.	This	argument	has	been	made	in	the	case	of	medical	devices,	owing	to	
the	existence	of	the	‘learning	curve’	and	rapid,	incremental	innovation	(5),	and	
interventions	for	rare	diseases,	because	of	the	difficulties	in	conducting	controlled	
clinical	studies	and	the	potential	existence	of	unique	aspects	of	‘social	value’	(6).	
Often	the	argument	is	not	for	a	completely	different	reference	case,	but	rather	for	
particular	attention	to	be	paid	to	a	number	of	specific	characteristics	of	the	health	
technologies	and	patient	population	concerned.	
	
Gene	therapy	is	a	novel	approach	that	uses	specific	genetic	material	to	treat	or	
prevent	disease.	These	technologies	may	allow	physicians	to	treat	a	disorder	by	
inserting	a	gene	into	patient’s	cells	instead	of	using	drugs	or	surgery.	Several	
approaches	to	gene	therapy	are	being	evaluated,	including	(1)	replacing	a	mutated	
gene	that	causes	disease	with	a	healthy	copy	of	the	gene,	(2)	inactivating,	or	
“knocking	out,”	a	mutated	gene	that	is	functioning	improperly,	and	(3)	introducing	a	
new	gene	into	the	body	to	help	fight	a	disease.	Although	representing	a	major	
breakthrough	in	therapy,	in	particular	for	those	diseases	that	currently	have	no	
effective	therapy,	gene	therapies	are	likely	to	be	very	expensive.		
	
In	the	case	of	gene	therapy,	there	is	a	difference	of	opinion	on	whether	a	specific	
methodologic	reference	case	is	required.	Hepple	et	al.	(7)	argue	that	the	general	
NICE	reference	case	can	be	applied	in	the	example	of	CAR-T	therapy.	Marsden	et	al	
(8)	question	this	argument	and	suggest	that	patients	with	rare,	genetic	diseases,	
along	with	the	gene	replacement	therapies	they	use,	present	a	unique	set	of	
conditions	that	warrant	equally	unique	analytic	approaches	to	estimating	value	for	
money.	Furthermore,	Jönsson	et	al	(9)	suggest	that	in	the	case	of	advanced	therapy	
medicinal	products	(ATMPs),	which	include	gene	therapy	approaches,	three	issues	
pose	challenges	for	current	methods:	the	uncertainty	about	future	costs	and	
benefits;	aspects	of	value	that	are	not	captured	in	the	quality-adjusted	life-year	
(QALY);	and	the	social	and	ethical	aspects	of	the	implications	of	discounting.	Finally,	
Garrison	et	al	(10)	argue	that	the	novel	aspects	of	value	provided	by	gene	therapies	
justif	a	higher	(cost-effectiveness)	decision-making	threshold.	
	
	
The	aim	of	this	paper	is	to	undertake	a	more	detailed	analysis	of	the	particular	
characteristics	of	gene	therapy	and	the	extent	to	which	these	suggest	modifications	
to	the	methods	used	in	economic	evaluation	and	the	applicability	of	the	general	
reference	case.	The	key	methodological	features	of	economic	evaluations	are	
discussed	in	turn.	For	this	paper	we	focus	on	the	most	severe	diseases	with	therapies	
that	have	the	potential	to	produce	large,	sustained	benefits.	
	
	
	
2.	Key	Methodology	Issues	
	
Genetic	diseases	are	highly	variable	in	terms	of	the	age	of	patients	at	first	clinical	
presentation,	symptoms,	morbidity	and	life	expectancy.	Gene	therapies	have	a	
number	of	particular	characteristics.	They	have	the	potential	to	deliver	benefits	that	
range	from	‘potentially	curative’	treatments	of	rare,	disabling	and	or	life-threatening	
conditions	often	targeting	young	children,	to	more	moderate	benefits	for	less	severe	
conditions.	Taken	individually,	none	of	these	characteristics	is	exclusive	to	gene	
therapy.	There	are	several	therapies,	of	all	types,	that	treat	severe,	disabling	or	life-
threatening	conditions.	There	are	many	other	treatments	for	rare	diseases	or	
diseases	that	affect	children.	Rather	it	is	the	confluence	of	these	various	
characteristics	in	the	case	of	gene	therapy	that	leads	to	specific	methodologic	
challenges	and	possibly	the	need	for	a	different	reference	case.	A	number	of	these	
challenges	are	described	below.	
	
2.1	Assessment	of	clinical	effectiveness	and	safety	
	
There	are	a	number	of	characteristics	of	gene	therapy	that	lead	to	challenges	in	the	
assessment	of	clinical	effectiveness	and	safety.	First,	because	some	new	therapies,	
including	gene	therapy,	may	bring	sizeable	benefits	in	high	unmet	need	areas,	or	life-
shortening	conditions,	policy	makers	have	implemented	a	number	of	regulatory	
pathways	to	accelerate	marketing	authorization.	These	include	accelerated	approval	
breakthrough	therapy	designation	and	priority	review	(11),	or	early	dialogue,	
accelerated	assessment	and	adaptive	pathways	(12,13).		
	
These	pathways	potentially	allow	rapid	patient	access	to	new	innovative	therapies,	
but	generally	result	in	regulatory	approval	with	limited	clinical	data.	The	large	
anticipated	benefits	may	outweigh	the	risks,	allowing	regulators	to	grant	marketing	
authorization,	while	the	actual	magnitude	of	this	benefit	remains	uncertain	at	the	
time	of	approval.	In	the	field	of	cancer	this	has	already	proven	to	be	problematic.		
Kim	and	Prasad	(14)	considered	36	cancer	drugs,	many	that	had	been	given	
accelerated	approval	by	the	FDA	based	on	a	surrogate	endpoint	(rate	or	response	or	
progression-free	survival).	Based	on	a	median	follow-up	of	4.4	years,	only	5	of	the	
drugs	had	by	that	time	demonstrated	improvement	in	overall	survival	in	randomized	
controlled	trials,	18	had	failed	to	show	any	improvement	and	11	had	no	results.	
	
This	raises	considerable	uncertainty	when	health	technology	assessment	agencies	or	
payers	attempt	to	understand	the	value	of	such	therapies.	The	primary	end	point	is	
often	a	surrogate,	raising	questions	about	the	validity	and	predictability	of	such	end	
points,	especially	in	rare,	poorly	studied	conditions.		The	short-term	evidence	
requires	extrapolation	to	long	term	benefit	often	with	little	insight	on	the	most	
appropriate	model,	leading	to	high	uncertainty	in	long-term	outcome.		And	because	
of	the	relatively	high	costs	of	these	new	classes	of	treatment,	payers,	be	they	
governments	or	private	insurers,	may	be	reluctant	to	support	coverage	where	the	
long-term	benefit	is	uncertain.		
	
Secondly,	gene	therapies	often	target	rare,	but	serious,	conditions.	This	raises	a	
number	of	challenges	in	the	conduct	of	conventional	randomized-controlled	trials.	
Given	the	small	patient	population,	recruitment	of	sufficient	patients	for	adequate	
enrollment	in	a	trial	is	often	difficult.	In	addition,	patients	or	their	caregivers	may	be	
reluctant	to	enter	in	a	placebo-controlled	trial	for	a	very	severe	life-shortening	
condition	when	an	experimental	therapy	exists	with	the	potential	to	offer	a	cure.	
Therefore,	clinical	studies,	even	if	randomized,	may	be	small	and	there	remains	a	
preponderance	of	single	arm,	uncontrolled	studies.	
	
A	recent	review	of	gene	therapy	studies	reported	that	47.2%	of	gene	therapy	clinical	
trials	enrolled	fewer	than	20	patients	and	that	the	median	size	of	the	trial	
populations	was	213	patients	(15).	As	gene	therapies	often	target	rare	conditions,	in	
order	to	increase	the	size	of	the	trial	population,	researchers	have	to	sacrifice	its	
homogeneity	by	including	participants	with	different	baseline	characteristics	or	from	
a	range	of	settings.	The	review	also	stated	that	20%	of	the	identified	trials	included	
both	children	and	adults.	Other	factors,	including	the	development	of	these	
therapies	in	a	limited	number	of	highly	specialized	centers	and	the	heterogeneity	of	
the	patient	population,	raise	questions	about	the	transferability	and	generalizability	
of	the	results	of	clinical	studies.	
	
Because	of	the	large	benefit	expected	from	such	therapies	and	the	lack	of	effective	
comparators,	manufacturers	often	gravitate	to	single	arm	small	trials,	in	one	single	
center	or	very	few	highly	specialized	centers.	However,	there	are	differences	of	
opinion	on	the	usefulness	of	these	studies	and	the	validity	of	historical	controls.	
Historical	cohorts	may	be	acceptable	when	the	population	is	relatively	
homogeneous,	when	confounding	factors	affecting	outcomes	are	well	known,	when	
patient	management	is	well	established	and	standardized,	when	the	primary	end	
point	is	objective	and	robust,	and	when	the	effect	size	of	the	new	therapy	is	
substantial	versus	the	historical	cohort.	In	this	case	a	matched	propensity	scoring	
method	may	be	helpful	to	appreciate	the	effect	size	of	the	benefit.	
	
As	mentioned,	these	challenges	are	not	unique	to	gene	therapy,	but	they	are	
particularly	concentrated	and	often	with	a	large	magnitude	in	these	treatments.	
Therefore,	in	designing	the	clinical	development	program	for	these	therapies	more	
attention	needs	to	be	paid	to:	
	
¥ minimizing	the	biases	in	observational	studies	used	to	establish	a	
reliable	historical	cohort	
¥ studying	heterogeneity	in	the	patient	population	
¥ understanding	the	confounding	factors	affecting	the	study	outcome	
¥ using	appropriate	statistical	methodology	for	historical	comparisons	
¥ considering	the	generalizability	of	the	clinical	data	
¥ validating	surrogate	end	points	
¥ using	appropriate	extrapolation	methods	to	estimate	long	term	
benefit.	
	
A	detailed	discussion	of	the	methodological	solutions	to	these	issues	is	beyond	the	
scope	of	this	paper,	but	any	reference	case	for	the	evaluation	of	gene	therapy	would	
need	to	pay	particular	attention	to	the	following	points.	
	
(i)	Small	or	single-arm	trials	
	
Where	trials	are	small,	or	consist	of	only	one	treatment	arm,	decision-makers	are	
likely	to	question	the	validity	of	the	clinical	evidence.	Therefore,	it	is	necessary	to	
find	data	from	outside	the	trial	in	order	to	provide	sufficient	evidence	of	treatment	
effect.	One	approach	is	to	find,	or	assemble,	a	historical	cohort	of	patients	treated	
before	the	advent	of	the	new	therapy,	that	can	be	used	as	a	comparator,	or	to	
supplement	the	trial	evidence.	An	example	is	the	single	arm,	multicenter	clinical	
development	program	for	the	chimeric	antigen	receptor	(CAR-T)	therapy	
axicabtagene	ciloleucel	for	patients	with	relapsed	or	refractory	large	B-cell	
lymphoma.	To	assess	comparative	effectiveness	and	safety,	patients	in	the	active	
therapy	arm	were	compared	to	an	historical	control	group	constructed	from	
observational	data	(16).	The	evaluation	by	the	Institute	for	Clinical	and	Economic	
Review	(ICER)	and	a	subsequent	cost-effectiveness	analysis	also	used	the	historical	
control	group	to	derive	estimates	of	incremental	benefit	(17).	
	
The	main	challenge	is	that	most	of	the	methodological	approaches	for	matching	or	
making	indirect	comparisons	require	data	on	patient	characteristics	that	can	be	used	
as	covariates	in	a	statistical	analysis.	These	data	can	be	collected	on	the	trial	
population	providing	this	need	is	anticipated	in	the	design	of	the	clinical	trial.	Finding	
equivalent	data	on	a	historical	cohort	can	be	more	challenging,	especially	when	
relying	on	existing	data	sources.		
	
An	ISPOR	Task	Force	(18)	developed	a	questionnaire	to	assess	the	relevance	and	
credibility	of	observational	studies,	the	‘relevance’	section	of	which	is		helpful	in	
judging	the	suitability	of	existing	data	sets.	However,	a	preferable	approach	would	
be	for	manufacturers	to	anticipate	the	likely	need	for	a	historical	cohort	in	advance.	
This	would	enable	the	consideration	of	factors	such	as:		(a)	ensuring	that	the	
patients	in	the	cohort	are	equivalent	to	those	expected	to	be	enrolled	in	the	trial	(b)	
collecting	the	data	on	patient	characteristics	for	use	as	covariates	and	(c)	ensuring	
that	the	measurement	outcomes	are	equivalent	to	those	planned	for	the	trial.	
	
(ii)	Surrogate	outcomes	
	
The	issues	in	the	use	of	surrogate	outcomes	in	clinical	trials	has	been	widely	
discussed	(19).	Sometimes	the	use	of	a	surrogate	outcome	is	unavoidable,	but	it	is	
important	to	know	whether	any	attempts	have	been	made	to	evaluate	and	validate	
it.	Several	approaches	to	the	validation	of	surrogates	exist	and	are	reviewed	in	Ciani	
et	al	(20).	Validation	can	be	considered	as	a	3-level	hierarchy:	(a)	biological	
plausibility,	(b)	the	association	between	the	surrogate	and	the	final	outcome	across	
cohorts	or	at	the	level	of	the	individual	patient,	or	(c)	evidence	that	the	technology	
improves	the	surrogate	and	the	final	outcome	in	several	clinical	trials.	The	third	level	
of	evidence	is	unlikely	to	be	available	in	the	case	of	gene	therapies	for	rare	diseases,	
but	the	same	surrogate	may	have	been	evaluated	in	similar	diseases	affecting	a	
larger	patient	population.	
	
	
	
However,	even	if	all	these	issues	were	successfully	tackled,	it	is	unlikely	that	all	the	
uncertainties	concerning	clinical	effectiveness	and	safety	will	be	reduced	to	a	level	
typically	accepted	by	payers,	or	those	conducting	health	technology	assessments.	
Furthermore,	as	in	all	new	therapies,	there	may	be	substantial	adverse	
consequences	of	treatment	that	are	currently	unknown,	a	concern	heightened	with	
truly	novel	approaches	such	as	gene	therapies.	There	is	also	uncertainty	over	the	
durability	of	treatment	and,	in	the	case	of	single	dose	therapy,	whether	an	additional	
dose	would	be	required	at	a	later	stage.	Therefore,	it	is	likely	that	a	prerequisite	
from	payers	for	reimbursement	of	gene	therapies	would	be	ongoing	monitoring	of	
the	patient’s	condition,	perhaps	linked	to	a	performance-based	risk-sharing	
arrangement	(21).	We	return	to	this	issue	later,	in	the	context	of	dealing	with	
uncertainty	in	economic	evaluations.	
	
2.2	Study	perspective	
	
In	many	jurisdictions,	the	study	perspective	for	cost-effectiveness	analyses	is	
specified	by	the	relevant	decision	maker	or	budget	holder.		For	example,	the	
National	Institute	for	Health	and	Care	Excellence	(NICE)	in	England	and	Wales	
specifies	a	National	Health	Service	(NHS)	and	personal	social	services	perspective	in	
its	cost-effectiveness	analyses	(3).	In	other	jurisdictions	(e.g	Sweden),	authorities	
prefer	a	societal	perspective,	accounting	for	all	costs	and	benefits	regardless	of	
where	they	fall.	(22).	
	
The	Second	Panel	on	Cost-Effectiveness	in	Health	and	Medicine	recommended	that,	
for	purposes	of	comparability,	relevance	and	completeness,	analysts	conducting	
cost-effectiveness	analyses	should	include	two	reference	cases	—	one	based	on	a	
societal	perspective	and	one	on	a	health	care	sector	perspective	(4).	As	Neumann	et	
al	noted,	“The	former	is	recommended	because	of	the	importance	of	capturing	the	
broad	consequences	of	health	interventions,	including	those	outside	the	health	care	
sector;	the	latter	is	a	nod	to	pragmatism,	because	it	is	more	closely	tied	to	the	
resource	implications	considered	by	health	sector	decision	makers”	(4).	The	Second	
Panel	emphasized,	however,	that	where	specific	decision	makers	have	been	
identified,	such	as	a	particular	public	or	private	payer,	analysts	may	wish	to	present	
results	from	this	decision	maker’s	perspective	in	addition	to	the	Reference	Case	
perspectives.	The	Panel	further	recommended	inclusion	of	an	“impact	inventory,”	a	
structured	table	listing	the	health	and	non-health-related	effects	of	an	intervention	
that	should	be	considered	in	a	societal	reference-case	analysis	(4).		
	
The	issue	of	perspective	is	critical	for	technologies	such	as	gene	therapies,	for	which	
there	is	the	prospect	of	long	term	benefits,	allowing	the	patient	to	live	a	relatively	
normal	life.	In	particular,	related	and	non-related	health	care	costs	would	need	to	be	
considered.	If	gene	therapy	does	lead	to	a	complete	resolution	of	the	patient’s	
health	problem,	it	may	result	in	a	substantial	reduction	in	related	health	care	costs,	
although	a	possible	increase	in	non-related	health	care	costs.		Inclusion	of	non-
health	care	costs	and	consequences,	such	as	impacts	on	caregivers	and	social	
services	and	on	economic	productivity,	can	have	profound	effects	on	whether	a	
therapy	is	deemed	cost-effective	at	a	given	price.		Where	therapy	is	for	children,	
these	effects	(including	impacts	on	educational	achievement	and	subsequent	
consequences	for	educational	costs,	productivity,	and	health	outcomes)	can	be	
substantial.		Under	a	societal	perspective,	all	of	these	current	and	future	non-health	
care	costs	and	consequences	would	need	to	be	considered	in	the	cost-effectiveness	
analysis.		Conducting	a	cost-effectiveness	analysis	of	gene	therapies	from	both	a	
societal	and	health	care	sector	perspective,	as	recommended	by	the	Second	Panel,	
can	highlight	for	decision	makers	the	difference	it	makes	when	broader	
consequences	are	considered.	
	
2.3	Valuation	of	benefits	
	
The	concept	of	“value”	in	assessing	health	technologies	remains	one	of	the	most	
debated	subjects	in	the	field.	Value	assessments	traditionally	include	a	definition	of	
benefits,	often	limited	to	the	gains	in	length	and	quality	of	life	(and	often	expressed	
as	QALYs),	cost	savings	and,	productivity	gains	incurred	by	the	patient	or	caregivers	
returning	to	work.	However,	a	need	for	a	broader	definition	of	value	continues	to	be	
debated.	The	ISPOR	Special	Task	Force	on	US	Value	Assessment	Frameworks	(23)	
recently	described	various	“novel”	elements	of	value	worthy	of	consideration,	many	
of	which	have	relevance	for	gene	therapies	(24).	(See	Figure	1)	
	
2.3.1	Severity	of	disease	
	
In	the	standard	application	of	QALYs,	each	QALY	gained	is	considered	to	be	of	the	
same	value,	no	matter	who	receives	it.	However,	many	of	the	diseases	treated	by	
gene	therapy	are	severe	or	life-threatening.	Severity	of	disease	has	been	discussed	
as	one	potential	element	of	value	that	is	not	adequately	considered	in	standard	cost-
effectiveness	estimates	(25).	In	terms	of	QALYs,	this	implies	that	a	gain	in	quality	of	
life	from,	say,	0.3-0.5	on	the	scale	is	worth	more	than	a	gain	from	0.5-0.7	(26).	It	has	
also	been	suggested	that	treatments	for	individuals	near	end-of-life	(or	proximity	to	
death)	may	be	more	valuable,	either	because	the	individuals	themselves	place	higher	
value	on	the	health	gain,	or	because	they	and	others	feel	that	society	should	give	
priority	to	treating	individuals	with	severe	disease	(27).	Some	recent	literature	links	
these	two	concepts	by	arguing	that	a	consideration	in	providing	treatment	should	be	
the	‘proportional	QALY	shortfall’	that	individuals	face,	namely	the	difference	
between	the	remaining	QALYs	they	are	likely	to	experience	with	their	current	
disease,	as	compared	with	a	healthy	person	of	their	age	(28).	
	
In	interpreting	the	literature	on	this	topic	and	its	relevance	to	gene	therapies,	a	key	
question	is	whether	individuals	are	responding	based	on	views	about	care	for	
themselves,	or	based	on	what	they	feel	society	should	do	for	others.	The	vast	
majority	of	studies	focus	on	the	second	issue,	although	sometimes	there	are	doubts	
about	the	basis	on	which	respondents	have	answered	the	questions	(28).	However,	
one	recent	study,	by	Taylor	et	al	(29)	suggests	that	individuals	place	a	greater	weight	
(for	themselves)	on	improvements	in	health	from	more	severe	health	states	than	on	
equivalent	improvements	from	less	severe	states.	Therefore,	therapies	that	improve	
the	health	of	individuals	in	severe	states	may	be	considered	to	be	of	higher	value.	
Some	of	the	gene	therapies	that	have	been	developed	so	far	are	for	serious	diseases,	
such	as	retinal	blindness	and	spinal	muscular	atrophy,	but	it	is	too	early	to	conclude	
that	this	trend	will	be	maintained	as	more	gene	therapies	are	developed.	
	
	
	
2.3.2	Value	to	caregivers	
	
The	severity	of	many	of	the	diseases	treated	by	gene	therapy	means	that	the	burden	
falling	on	caregivers	is	likely	high.	The	burden	has	two	components,	the	emotional	
stress	of	seeing	a	close	relative	or	friend	suffering	from	a	serious	disease	and	the	
time	spent	in	providing	informal	care.	The	emotional	component	may	be	particularly	
high	in	the	case	of	caring	for	a	sick	child.	A	number	of	estimates	of	caregiver	burden	
exist	in	the	literature,	mainly	focusing	on	the	value	of	the	time	spent	in	caring	(30),	
although	some	methods	estimate	the	broader	impact	on	caregiver	wellbeing	(31).	
Although	the	burden	on	caregivers	is	widely	recognized,	it	is	infrequently	measured	
in	economic	evaluations	(32).		
	
2.3.3	Insurance	value	
	
Insurance	value	relates	to	the	benefit	individuals	derive	from	knowing	that	they	are	
protected	–	physically	(by	having	access	to	treatment	if	they	require	it)	and	
financially	(in	case	they	have	to	incur	the	cost	of	treatment).	While	the	insurance	
value	can	be	applied	to	any	health	technology,	Jena	and	Lakdawalla	(6)	argue	that	
insurance	value	is	disproportionately	high	in	the	case	of	rare,	serious	diseases,	since	
they	pose	greater	risk	to	healthy	consumers,	given	that	they	involve	bigger	
reductions	in	wellbeing	in	the	event	of	illness	to	themselves	or	a	loved	one.	Also,	
unlike	the	conventional	measures	of	the	value	of	therapy,	insurance	value	applies	to	
all	consumers,	not	just	those	who	suffer	from	the	relevant	disease.	
	
2.3.4	Scientific	spillovers	
	
‘Scientific	spillovers’	refer	to	the	knowledge	created	in	the	development	of	products	
that	have	broad	benefits	for	society	as	the	information	becomes	a	“public	good”	and	
is	used	in	the	discovery	of	other	therapies.	That	is,	when	a	drug	with	a	new	
mechanism	of	action	is	discovered,	it	may	facilitate	the	development	of	other	
therapies	that	will	deliver	benefits	to	future	patients.	Given	that	gene	therapy	is	in	
early	stages	of	development,	it	is	possible	that	other	discoveries	will	follow,	but	the	
extent	of	it	is	unknown	at	this	point.	Scientific	spillovers	have	been	documented	
using	National	Institutes	of	Health	funding	as	the	‘intervention’	and	clinical	trial	
starts	as	the	‘outcome’	(33).	However,	the	value	of	innovation	is	notoriously	hard	to	
assess	and	there	is	debate	about	whether	it	is	best	funded	through	higher	product	
prices	or	other	methods	and	whether,	in	giving	a	price	premium	for	the	innovation,	
payers	risk	paying	twice	if	the	developers	of	the	subsequent	therapies	also	require	a	
reward	for	the	innovation	they	represent.		
	
2.3.5	Incorporating	broader	elements	of	value	into	decision-making	
Ideally,	the	various	elements	of	value	mentioned	above	would	need	to	be	measured	
and	then	combined	with	the	conventional	benefits	(e.g.	QALYs)	to	give	an	overall	
assessment	of	the	value	of	gene	therapy.	Lakdawalla	et	al	(24)	offer	some	
suggestions	for	how	these	measurements	could	be	made,	many	of	which	are	based	
on	willingness-to-pay	approaches.	However,	in	another	report	of	the	ISPOR	Special	
Task	Force,	Phelps	et	al	(34)	point	to	some	of	the	difficulties	in	aggregation.	They	
argue	that	monetary	valuation	within	a	cost-benefit	analysis	framework	raises	
concerns	of	equity	and	fairness.	The	main	alternative	approach	to	aggregation,	
multi-criteria	decision	analysis	(MCDA),	shows	promise	but	has	had	limited	
application	in	real-life	decision-making	settings	and	more	research	is	needed	on	key	
aspects	of	MCDA	modeling.		
In	practice,	payers	and	those	undertaking	health	technology	assessments	either	use	
‘deliberative	decision-making’	to	incorporate	these	novel	elements	of	value,	or	
modify	their	decision	rule	(e.g.	raise	their	cost-effectiveness	threshold)	to	
accommodate	them	(35).	One	of	the	criticisms	of	deliberative	decision-making,	
where	decision-makers	consider	elements	of	value	that	are	not	included	in	the	
estimate	of	the	incremental	cost-effectiveness	ratio,	is	that	these	discussions	are	
often	unstructured	and	lacking	in	transparency.	In	Scotland	the	Scottish	Medicines	
Consortium	(36)	has	a	more	structured	approach	that	defines	a	series	of	‘modifiers’	
to	their	decision-making	threshold	that	include	factors	such	as	the	severity	of	
disease,	evidence	of	a	substantial	improvement	in	life	expectancy,	absence	of	other	
therapeutic	options	of	proven	value,	and	bridging	to	another	proven	therapy.		
In	Sweden,	although	there	is	no	official	cost	per	QALY	threshold,	the	Dental	and	
Pharmaceutical	Benefits	Board	(TLV)	makes	adjustments	in	its	decisions	to	account	
for	severity	of	disease	(37).	More	recently,	in	an	example	particularly	relevant	to	
gene	therapy,	the	National	Institute	for	Health	and	Care	Excellence	in	England	has	
stated	that	it	will	consider	a	cost-effectiveness	threshold	up	to	£100,000	per	QALY,	in	
its	Highly	Specialized	Treatments	Programme,	in	situations	where	the	new	therapy	
gives	a	gain	to	patient	of	more	than	10	QALYs	over	their	lifetime,	rising	to	£300,000	
per	QALY	if	the	therapy	gives	a	gain	of	30	QALYs	(38).	This	is	considerably	higher	than	
the	threshold	of	£20,000	per	QALY	in	the	Institute’s	‘standard’	Technology	Appraisal	
Programme.		
From	the	perspective	of	gene	therapy,	it	would	be	important	to	have	the	potential	to	
identify	the	elements	of	value	mentioned	above.	Then	it	would	be	for	decision-
makers	to	decide	whether	to	consider	them	in	their	decision-making	processes.	
2.3.6	Time	horizon	and	discount	rates	
	
The	general	recommendation	for	the	choice	of	time	horizon	in	economic	evaluations	
is	that	it	should	be	long	enough	to	capture	all	the	relevant	costs	and	benefits	of	the	
treatment	being	evaluated	(4,39).	Gene	therapies	used	in	severe	or	life-threatening	
conditions	have	the	potential	to	extend	individuals’	life	expectancy	considerably,	
which	suggests	projecting	the	predicted	costs	and	outcomes	over	a	long	period	of	
time,	probably	a	person’s	lifetime.	Therefore,	it	would	make	sense	to	present	the	
analysis	using	different	time	horizons	in	a	series	of	scenario	analyses,	with	the	
different	time	horizons	relating	to	different	levels	of	knowledge	about	treatment	
effect.	For	example,	depending	on	the	length	of	follow-up	in	existing	clinical	studies,	
there	may	be	good	data	on	life	expectancy	over	5	years,	but	limited	data	over	10	or	
15	years.	
	
Most	reference	cases	for	economic	evaluation	recommend	or	require	that	the	same	
discount	rate	should	be	applied	to	both	costs	and	benefits.	Jönsson	et	al	(9)	question	
this	in	the	case	of	advanced	therapy	medicinal	products	(ATMPs),	where	often	there	
is	a	large	up-front	cost	if	the	therapy	is	delivered	in	a	single	dose,	with	benefits	
stretching	far	into	the	future.	They	also	point	out	that	there	is	a	minority	of	national	
HTA	bodies	(e.g.	in	Belgium,	Netherlands	and	Poland)	that	allow	benefits	to	be	
discounted	at	a	lower	rate	than	costs.	Also,	in	the	case	of	prevention	programs,	
which	also	typically	have	a	high	up-front	cost,	NICE	in	England	and	Wales	suggests	
that	analysts	explore	the	implications	of	the	discount	rate	for	the	estimates	of	
benefits	and	hence	the	cost-effectiveness	of	the	program	(40).	Another	issue,	
relating	to	gene	therapy,	is	that	individuals	may	receive	additional	utility	in	
anticipation	if	they	consider	that	their	disease	has	been	cured.	The	same	argument	
has	been	made	in	the	context	of	vaccination	programs;	namely,	if	individuals	
consider	that	the	vaccine	offers	them	protection	from	the	disease,	the	benefit	is	
received	immediately,	not	at	some	point	in	the	future	(41).	
	
At	this	point	there	is	not	a	strong	enough	case	for	departing	from	the	general	
methodological	principal	of	discounting	costs	and	benefits	at	the	same	rate.	
However,	considering	the	arguments	above,	we	recommend	that	the	analyst	
explores	the	impact	of	using	different	discount	rates,	for	costs	and	benefits.	In	
general,	choosing	a	lower	discount	rate	will	be	more	favorable	to	gene	therapies	if	a	
major	proportion	of	the	cost	occurs	in	the	first	year,	since	the	benefits	are	spread	
over	a	long	period	of	time.	
	
2.4	Dealing	with	uncertainty	
	
Uncertainty	concerning	the	long-term	effects	of	gene	therapy	has	already	been	
mentioned	several	times	in	this	paper.	The	standard	analytic	approach	in	economic	
evaluation	for	dealing	with	parameter	uncertainty	would	be	to	use	a	model	to	
extrapolate	long-term	costs	and	benefits	using	the	best	information	possible	and	
then	to	conduct	a	probabilistic	sensitivity	analysis	(PSA).	This	would	then	form	the	
basis	for	a	value	of	information	analysis	to	help	determine	what	future	investments	
in	data	collection	should	be	made	to	reduce	the	decision	uncertainty.	There	may	also	
be	structural	uncertainty	in	designing	any	economic	model.	For	example,	should	the	
model	include	a	possibility	of	adverse	events,	the	nature	of	which	is	completely	
unknown?	
	
However,	in	the	case	of	gene	therapy	it	is	likely	that	the	PSA	would	generate	a	wide	
confidence/credibility	interval	around	the	incremental	cost-effectiveness	ratio	
(ICER).	Also,	it	is	fairly	clear	that	the	main	unknown	is	the	long	term	effectiveness	of	
gene	therapy	and	that	the	other	major	parameter	in	the	economic	evaluation	is	the	
incremental	cost	of	gene	therapy	as	compared	with	the	current	standard	of	care.	
Since	most	of	the	cost	of	gene	therapy	would	be	incurred	up-front,	it	is	largely	
known	already.		
	
This	suggests	that	the	capability	of	analysis	to	help	deal	with	the	uncertainty	is	
limited.	From	a	decision-making	perspective,	the	most	effective	way	of	dealing	with	
the	uncertainty	would	be	to	devise	a	performance-based	risk-sharing	arrangement	
linking	payment	with	the	accumulated	knowledge	about	the	effectiveness	of	the	
therapy.	The	contribution	of	value	of	information	analysis	would	be	to	help	
determine	the	main	features	of	that	arrangement	(42).	
	
The	issues	in	developing	these	arrangements	depend	on	the	nature	of	the	health	
care	system,	whether	public	or	private,	single	payer	or	multi-payer.	Karlsberg	
Schaffer	et	al	(43)	report	some	reluctance	on	the	part	of	payers	to	assume	too	much	
financial	risk,	or	to	participate	in	payment	arrangements	that	add	a	lot	of	complexity	
to	already	complicated	processes	for	coverage	and	reimbursement.	While	various	
insurance	systems	are	structured	in	a	way	that	introduce	complexity,	most	notably	in	
the	US,	the	most	obvious	way	to	solve	for	the	unknown	elements	is	to	pay	for	the	
therapy	over	a	set	period	of	time	rather	than	entirely	upfront.	By	paying	at	a	level	
commensurate	with	results,	which	might	be	structured	as	partial	payment	for	less	
than	full	efficacy	or	elimination	of	future	payments	under	certain	conditions,	it	is	
possible	to	address	concerns	by	payers	that	beneficiaries	will	not	receive	the	full	
value	of	the	therapy.	
	
Apart	from	the	reluctance	of	payers	to	embark	on	these	arrangements,	they	also	
pose	a	range	of	methodological	and	practical	challenges,	in	study	design,	
involvement	of	the	relevant	parties	and	data	collection	and	monitoring	(44).	In	multi-
payer	systems	like	that	in	the	US,	there	is	the	additional	complication	that	
individuals	may	change	insurance	plans.	Despite	these	challenges,	the	advent	of	
gene	therapy	will	likely	give	an	increased	impetus	to	solving	them.	
	
It	is	also	important	to	agree	on	what	a	“fair”	price	is	for	the	baseline	case	in	which	
the	gene	therapy	fully	delivers	on	its	promises.	Economic	evaluation,	conducted	
along	the	lines	specified	above,	can	make	an	important	contribution	to	price	
determination.	It	also	raises	the	issue	of	how	many	years	of	cost	savings	should	be	
factored	into	the	price.	The	challenge	of	undertaking	these	assessments	has	fallen	to	
different	entities	in	various	countries,	and	it	is	undeniable	that	even	in	countries	like	
the	US,	where	basing	reimbursement	decisions	on	metrics	like	QALYs	has	proven	
challenging	and	controversial,	payers	and	others	involved	in	the	reimbursement	
decisions	are	paying	closer	attention	to	economic	evaluations.		
	
It	should	also	be	noted	that	there	are	other	considerations	that	play	into	the	
question	of	a	fair	price:	comparison	to	other	treatments	with	similar	characteristics;	
the	size	of	the	addressable	population;	the	margins	to	the	manufacturer,	and	so	on.	
Where	there	is	no	existing	therapy	for	the	condition	in	which	the	gene	therapy	is	
indicated,	decision-makers	will	be	concerned	about	affordability	as	well	as	value	for	
money	(43).	Although	we	are	recommending	performance-based	risk-sharing	
arrangements	primarily	as	a	way	of	dealing	with	uncertainty,	these	arrangements	
may	also	have	the	effect	of	spreading	payments	over	time,	which	will	help	address	
affordability	concerns.		
	
Not	all	gene	therapies	are	for	conditions	for	which	there	are	no	alternative	
therapies.	In	some	cases	gene	therapy	may	be	a	replacement	for	treatments	that	are	
already	very	expensive,	such	as	prophylaxis	for	hemophilia	A	in	patients	with	
inhibitors	(45).	In	such	cases	gene	therapy	could	potentially	command	a	very	high	
price.	However,	where	there	are	multiple	alternative	treatments	for	a	given	therapy,	
whether	two	or	more	gene	therapies	or	a	variety	of	treatment	types,	the	latter	of	
which	we	are	likely	to	see	with	hemophilia	for	example,	market	competitive	forces	
will	also	be	an	important	factor.	
	
Finally,	it	should	be	noted	that	those	making	policy	determinations	frequently	
question	initial	data,	because	the	settings	are	generally	ideal	and	most	conducive	to	
demonstrating	positive	results,	as	opposed	to	the	environment	of	a	busy	clinician,	
who	may	not	precisely	be	following	the	recommendations	in	clinical	guidelines.		For	
that	reason,	as	well	as	the	fact	that	many	gene	therapies	coming	to	market	have	
been	tested	on	relatively	small	numbers	of	patients	in	ideal	conditions,	one	can	
argue	that	innovative	payment	models	are	most	important	when	a	new	therapy	is	
first	released	and	may	be	less	of	a	requirement	once	real	world	evidence	has	
accumulated	that	creates	greater	agreement	about	the	likely	impact	of	treatment.	
	
3.	A	Proposed	Checklist	for	Assessing	Gene	Therapy	
	
One	approach	for	dealing	with	the	additional	considerations	outlined	above	would	
be	to	produce	a	combined	estimate	of	the	value-added	by	gene	therapy.	However,	
as	mentioned	earlier,	this	approach	is	unlikely	to	be	successful,	owing	to	the	
uncertainties	in	the	measurement	of	many	of	the	elements	of	value	and	in	the	ways	
of	combining	them	in	a	single	estimate.	Rather,	a	more	helpful	approach	would	be	to	
identify	the	main	considerations	in	the	assessment	of	gene	therapy	in	a	way	that	
would	assist	decision-makers	in	their	deliberative	decision-making	processes.		
	
The	Second	Panel	on	Cost-Effectiveness	in	Health	and	Medicine	advanced	the	idea	of	
an	“Impact	Inventory”	to	describe	consequences	of	interventions	both	inside	and	
outside	of	the	formal	health	care	sector,	and	to	aid	analysts	in	providing	a	complete	
and	transparent	account	of	the	reference	case	(4,46).	As	Sanders	et	al.	(46)	note,	“if	
the	results	in	the	societal	reference	case	differ	substantially	from	those	in	the	health	
care	sector	reference	case,	all	identified	effects	should	ideally	be	quantified,	valued	
if	possible,	and	reported	in	the	results	section.”	Completing	an	Impact	Inventory	may	
be	particularly	important	for	gene	therapies,	given	that	such	therapies	can	have	
important	non-health	consequences	(e.g.,	effects	on	family	caregivers,	education	
costs,	economic	productivity).	
	
In	the	spirit	of	the	Second	Panel’s	Impact	Inventory,	it	may	also	be	useful	to	develop	
and	apply	a	separate	checklist	for	economic	evaluations	of	gene	therapies	in	order	to	
clarify	for	audiences	whether	and	to	what	extent	other	key	elements	affecting	gene	
therapies	have	been	identified	and	considered	in	analyses.	Figure	2	displays	a	sample	
checklist.		The	first	section	itemizes	characteristics	of	gene	therapy	related	to	clinical	
effectiveness	assessments,	including:		whether	the	therapies	are	in	areas	of	high	
unmet	need	or	life-shortening	conditions;	whether	surrogate	endpoints	have	been	
used;	the	sample	size	and	duration	of	pivotal	clinical	trials	used	to	approve	the	
drugs;	whether	trials	were	single	arm,	uncontrolled	studies;	whether	trials	included	
children	and/or	adults,	whether	studies	were	conducted	in	highly	specialized	
centers,	and	to	what	extent	trial	results	can	be	transferred	and	generalized	to	other	
settings.	
	
The	second	section	relates	to	the	valuation	of	benefits	for	gene	therapies,	
highlighting	whether	the	study	incorporated	various	novel	elements	of	value.		As	
noted,	such	elements	may	have	heightened	relevance	for	gene	therapies.		The	
checklist	contains	items,	for	example,	to	convey	whether	the	economic	evaluation	
considered	and	separately	valued	the	therapy	based	on	severity	of	disease	(i.e.,	
whether	a	gene	therapy	that	improves	the	health	of	individuals	in	severe	states	is	
given	a	higher	value),	as	well	as	caregiver	burden,	insurance	value,	scientific	
spillovers,	and	real	option	value.	
	
The	third	section	relates	to	any	additional	considerations,	which,	based	on	the	
discussion	above,	would	be	the	attention	paid	to	the	impact	of	discounting	and	the	
handling	of	uncertainty.	As	noted	earlier,	taken	individually,	none	of	the	various	
elements	in	the	checklist	is	exclusive	to	gene	therapy;	rather	it	is	the	confluence	of	
these	various	characteristics	that	leads	to	specific	methodologic	challenges	and	
possibly	the	need	for	a	different	approach	to	economic	evaluation.		The	checklist	can	
serve	as	an	organizing	device,	signaling	to	readers	of	economic	evaluations	the	
extent	to	which	various	factors	were	identified	and	considered	formally	in	analyses.	
	
4.	Conclusions	
	
Gene	therapies	do	have	a	number	of	particular	characteristics	that	suggest	that	the	
approach	to	economic	evaluation	should	be	modified.	However,	in	our	view,	these	
modifications	do	not	imply	the	need	for	a	new	reference	case.	Rather,	they	suggest	
that	particular	aspects	of	the	evaluation	need	further	attention.	We	propose	an	
additional	checklist	that	can	be	used	by	analysts	to	determine	which	aspects	of	the	
evaluation	should	be	considered	further.	Finally,	there	are	some	characteristics	of	
gene	therapy,	such	as	the	uncertainties	about	long-term	benefits,	that	are	not	easily	
dealt	with	by	developments	in	methods.	For	these	aspects	we	also	need	innovations	
in	payment	systems	to	accompany	any	developments	in	methods.		
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Figure	1	Potential	Elements	of	Value	to	Consider	in	Economic	Evaluations	
	
	
Source:	Lakdawalla	et	al	(24)	
	
	
	
	
	
	
	
	
	
		
	
	
	
	
	
	
	
	
	
	
 
Figure 2: Checklist for Assessing Gene Therapies  
  Yes No Notes 
Clinical Effectiveness 
  
 Surrogate endpoint used □ □ Validation given? 
 
Rare disease □ □ Prevalence _____ 
 
Serious condition □ □  
 
Single-armed trial □ □   Matched historical 
cohort used? 
 
Pediatric population  □ □ Age range _____ 
Reporting of adverse consequences 
and risks  
□ □ 
     Size of clinical trial _____ number of patients  
Length of clinical trial _____ duration in months  
Extrapolation to long-term outcomes _____ duration in months 
  
Elements of Value 
  
Quantification  
Severe disease □ □ 
 Value to caregivers □ □ 
 Insurance value □ □ 
 Scientific spillovers □ □ 
    
 Lack of alternatives □ □ 
 Substantial improvement in life 
expectancy 
□ □ 
  
Other Considerations   Notes 
Discounting   
 
Different discount rates explored □ □ 
 Uncertainty   
 Alternative payment models □ □ 
 explored            
Notes:  
   
		 	
	 	
		
	
	 	
	
	
	
	
	
	
	
	
	
	
	 	
	 	
		
	
	
	
